Dose Reduction and Discontinuation With Anti-Fibrotic Medications
NCT05779007 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2778
Last updated 2025-07-28
Summary
The overarching aim of our study is to assess the incidence of dose reduction and discontinuations for pirfenidone and nintedanib.
Conditions
Interventions
- DRUG
-
Pirfenidone
- DRUG
-
Nintedanib
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-04-18
- Primary Completion
- 2023-07-14
- Completion
- 2023-07-14
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Observational Study to Evaluate Disease Course and Outcomes in Patients Treated With Esbriet (Pirfenidone) for Idiopathic Pulmonary Fibrosis (IPF) in Canada
NCT02552849 ·Status: COMPLETED
-
Detection of Early Idiopathic Pulmonary Fibrosis
NCT03457935 ·Status: ACTIVE_NOT_RECRUITING
-
Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With Nintedanib
NCT03710824 ·Status: COMPLETED
-
Inhalation Profiling of Idiopathic Pulmonary Fibrosis (IPF) Patients
NCT02058602 ·Status: COMPLETED ·Phase: PHASE1
-
Correlation Between Changes in Lung Function and Changes in Cough and Dyspnoea in Nintedanib-treated Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) Patients
NCT05503030 ·Status: ACTIVE_NOT_RECRUITING
-
Efficacy and Safety of Early Antifibrotic Therapy for Non-progressive Fibrotic Interstitial Lung Disease
NCT07141810 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Quality of Life Study in Participants With IPF Under Pirfenidone Treatment
NCT03115619 ·Status: COMPLETED
-
A Study to Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) During the Peri-Diagnostic Period
NCT03261037 ·Status: COMPLETED ·Phase: NA
-
Optimising Screening for Early Disease Detection in Familial Pulmonary Fibrosis
NCT05367349 ·Status: UNKNOWN
-
IPF Italian Observational Study (FIBRONET) in Idiopathic Pulmonary Fibrosis
NCT02803580 ·Status: COMPLETED
-
Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis
NCT02230982 ·Status: NO_LONGER_AVAILABLE
-
A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis
NCT07080125 ·Status: ACTIVE_NOT_RECRUITING
-
Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)
NCT00373841 ·Status: RECRUITING
-
Oxygen Therapy Use in Patients With Fibrotic Interstitial Lung Disease
NCT05957198 ·Status: COMPLETED
-
Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease
NCT02055222 ·Status: COMPLETED
-
A Study To Investigate The Ability To Use 18FDG PET Scanning To Monitor The Effectiveness Of New Drugs In COPD Patients
NCT00472264 ·Status: TERMINATED
-
It's Not JUST Idiopathic Pulmonary Fibrosis Study
NCT03670576 ·Status: UNKNOWN
-
Exhaled Breath Condensate Biomarkers and Cough in IPF
NCT02630940 ·Status: COMPLETED
-
Inspiratory Effort Assessed Through Nasal Pressure Measurement in Patients With Idiopathic Pulmonary Fibrosis
NCT05310669 ·Status: RECRUITING
-
A Multicenter Prospective Study of Risk Factors in Progressive Pulmonary Fibrosis
NCT05895409 ·Status: RECRUITING
-
INREAL - Nintedanib for Changes in Dyspnea and Cough in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease (ILD) With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation
NCT04702893 ·Status: COMPLETED
-
Investigating Idiopathic Pulmonary Fibrosis in Greece
NCT03074149 ·Status: COMPLETED
-
Self-monitoring of Spirometry & Symptoms Via patientMpower App in Idiopathic Pulmonary Fibrosis
NCT03744598 ·Status: TERMINATED
-
Investigating Incidental Pulmonary Nodules in Underserved Communities
NCT05738031 ·Status: WITHDRAWN
-
Breath Analysis in Lung Fibrosis
NCT02437448 ·Status: COMPLETED